Genomics BioSci & Tech. Co.,Ltd. (4195.TWO)
TWD 18.45
(-0.27%)
TWD 18.45
(-0.27%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -96.02 Million | -21.12 Million | -27.76 Million | -18.83 Million | 78.33 Million |
| Net Income | -167.94 Million | 72.26 Million | 12.09 Million | -3.1 Million | 84.93 Million |
| Depreciation & Amortization | 39.97 Million | 32.97 Million | 33.95 Million | 35.2 Million | 38.88 Million |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | 629 Thousand | 912 Thousand | - | 379 Thousand | - |
| Change in working capital | -53.61 Million | -22.77 Million | -32.61 Million | -63.11 Million | 11.75 Million |
| Other non-cash items | 2.67 Million | 1.63 Million | -68.67 Million | 2.56 Million | -57.23 Million |
| Investing Cash Flow | -157.73 Million | 28.82 Million | -317.63 Million | -122.88 Million | 89.85 Million |
| Investments in PPE | -151.36 Million | -94.23 Million | -94.81 Million | -46.43 Million | -20.97 Million |
| Acquisitions | - | 5.91 Million | -124.77 Million | - | - |
| Investment purchases | -7 Million | - | -114 Million | -72.81 Million | - |
| Sales/Maturities of investments | - | 117.54 Million | 10.52 Million | - | - |
| Other Investing Activities | 632 Thousand | -409 Thousand | -3.09 Million | -3.63 Million | 110.83 Million |
| Financing Cash Flow | 190.06 Million | 197.35 Million | -22.13 Million | 217.37 Million | -7.5 Million |
| Debt repayment | -53.11 Million | -136.17 Million | -18.51 Million | -46.2 Million | -9.12 Million |
| Dividends payments | -7.1 Million | -2000.00 | -35 Thousand | -69.47 Million | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | 150.4 Million | 65.52 Million | - | - | - |
| Other Financing Activities | 150.4 Million | 115.52 Million | 79 Thousand | 243.91 Million | 1.62 Million |
| Accounts receivables | -782 Thousand | -20.16 Million | -6.61 Million | 4.98 Million | -18.55 Million |
| Accounts payables | -10.73 Million | - | - | - | - |
| Inventory | -10.81 Million | -20.58 Million | 1.83 Million | -14.43 Million | 5.85 Million |
| Other working capital | -24 Million | 3.8 Million | -34.47 Million | -23 Million | 24.45 Million |
| Cash at beginning of period | 317 Million | 107.49 Million | 476.94 Million | 401.13 Million | 240.76 Million |
| Cash at end of period | 253.03 Million | 317 Million | 107.49 Million | 476.94 Million | 401.13 Million |
| Capital Expenditure | -151.36 Million | -94.23 Million | -94.81 Million | -46.43 Million | -20.97 Million |
| Effect of forex changes on cash | -271 Thousand | 4.45 Million | -1.91 Million | 152 Thousand | -324 Thousand |
| Net cash flow / Change in cash | -63.97 Million | 209.5 Million | -369.44 Million | 75.8 Million | 160.36 Million |
| Free Cash Flow | -247.39 Million | -115.36 Million | -122.57 Million | -65.27 Million | 57.35 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -34.36 Million | -34.36 Million | -44.88 Million | -167.94 Million | -44.88 Million | -39.14 Million |
| Depreciation & Amortization | 15.19 Million | 15.19 Million | 11.65 Million | 39.97 Million | 11.65 Million | 8.02 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 7000.00 | - | - | 629 Thousand | - | 314.5 Thousand |
| Change in working capital | -11.56 Million | -11.56 Million | -6.36 Million | -53.61 Million | -6.36 Million | -11.43 Million |
| Other non-cash items | 7.77 Million | 7.78 Million | 22.86 Million | 2.67 Million | 22.86 Million | 10.95 Million |
| Investing Cash Flow | -78.26 Million | -78.26 Million | -38.47 Million | -157.73 Million | -38.47 Million | -40.39 Million |
| Investments in PPE | -68.75 Million | -68.75 Million | -35.57 Million | -151.36 Million | -35.57 Million | -39.55 Million |
| Acquisitions | 108.68 Million | - | - | - | - | - |
| Investment purchases | -18.5 Million | - | - | -7 Million | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -9.5 Million | -9.5 Million | -2.9 Million | 632 Thousand | -2.9 Million | -839.5 Thousand |
| Financing Cash Flow | 105.11 Million | 105.11 Million | 47.38 Million | 190.06 Million | 47.38 Million | 47.64 Million |
| Debt repayment | -105.13 Million | - | - | -53.11 Million | - | - |
| Dividends payments | - | - | -3.55 Million | -7.1 Million | -3.55 Million | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | 150.4 Million | - | - |
| Other Financing Activities | 105.11 Million | 105.11 Million | 50.94 Million | 150.4 Million | 50.94 Million | 47.64 Million |
| Accounts receivables | 4 Million | 4 Million | 9.24 Million | -782 Thousand | 9.24 Million | -9.63 Million |
| Accounts payables | 5.5 Million | - | - | - | - | - |
| Inventory | -10.81 Million | -10.81 Million | -5.98 Million | -10.81 Million | -5.98 Million | 574.5 Thousand |
| Other working capital | -4.75 Million | -4.75 Million | -9.62 Million | -24 Million | -9.62 Million | -2.37 Million |
| Cash at beginning of period | 265.03 Million | - | - | 317 Million | - | - |
| Cash at end of period | 4.19 Million | 4.19 Million | -7.94 Million | 253.03 Million | -7.94 Million | -24.03 Million |
| Capital Expenditure | -68.75 Million | -68.75 Million | -35.57 Million | -151.36 Million | -35.57 Million | -39.55 Million |
| Effect of forex changes on cash | 287.5 Thousand | 287.5 Thousand | -128.5 Thousand | -271 Thousand | -128.5 Thousand | -7000.00 |
| Net cash flow / Change in cash | -260.83 Million | 4.19 Million | -7.94 Million | -63.97 Million | -7.94 Million | -24.03 Million |
| Free Cash Flow | -91.7 Million | -91.7 Million | -52.3 Million | -247.39 Million | -52.3 Million | -70.83 Million |
LFMDP
6471
WI4
OBK
CHCI
ANSLY